Coinfection
Incidence of Liver Cancer Is Increasing Among People with HIV/HCV Coinfection
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 13 July 2016 00:00
- Written by Michael Carter
Incidence of liver cancer is increasing among people with HIV co-infection, an international team of investigators report in the June 15 online edition of Clinical Infectious Diseases. Researchers from Europe and Canada pooled data gathered between 2001 and 2014 from 6 prospective cohorts and found that incidence of hepatocellular carcinoma (HCC) increased, but the incidence of serious liver related events -- decompensated liver disease or liver-related death -- declined.
EASL 2016: Does Having HIV Affect Response to Hepatitis C Treatment?
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 04 May 2016 00:00
- Written by Liz Highleyman
A study from the U.S. Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral (DAA) therapy for hepatitis C, while a Spanish study showed that HIV/HCV coinfected people were less likely to be cured. These conflicting findings, presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona, indicate that the interactions between HIV and hepatitis C are still not fully understood.
CROI 2016: Sofosbuvir/ Velpatasvir for Hepatitis C Can Be Administered with Most Antiretrovirals
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 08 March 2016 00:00
- Written by Liz Highleyman
Sofosbuvir/velpatasvir, a forthcoming combination that effectively treats all hepatitis C virus (HCV) genotypes, can be safely used with most boosted antiretrovirals for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last week in Boston.
EASL 2016: Sofosbuvir/ Velpatasvir Cures 95% of HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Monday, 18 April 2016 00:00
- Written by Liz Highleyman
A dual regimen of sofosbuvir plus velpatasvir was well-tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic hepatitis C coinfection, according to results from the Phase 3 ASTRAL-5 trial presented at the 2016 EASL International Liver Congress last week in Barcelona.
EACS 2015: Successful Hepatitis C Treatment Lowers Risk of Death for HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 28 October 2015 00:00
- Written by Liz Highleyman
Hepatitis C treatment that leads to sustained virological response (SVR) -- generally regarded as a cure -- was associated with a reduced risk of liver-related death and improved overall survival in an analysis of 3500 HIV and hepatitis C virus (HCV) coinfected patients, according to a presentation at the 15th European AIDS Conference last week in Barcelona. A related study found that while some liver-related events are declining over time, liver cancer remains a risk for coinfected people.
CROI 2016: HIV/HBV Coinfection Linked to Worse Immune Recovery and Death
- Details
- Category: HIV/HBV Coinfection
- Published on Wednesday, 06 April 2016 00:00
- Written by Liz Highleyman
HIV-positive people with hepatitis B virus (HBV) coinfection had impaired CD4 cell recovery after starting antiretroviral (ART) and a higher risk of death than those without hepatitis B, but use of ART regimens containing tenofovir significantly reduced mortality, according to a study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)in Boston.
IDWeek 2015: Sofosbuvir + Daclatasvir Demonstrates High Cure Rates for HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Monday, 19 October 2015 00:00
- Written by Liz Highleyman
Nearly all people with HIV and genotype 1-4 HCV coinfection treated for 12 weeks with an interferon-free regimen of sofosbuvir (Sovaldi) plus daclatasvir (Daklinza) achieved sustained virological response in the ALLY-2 trial, but 8 weeks did not work as well, according to a report in the August 20 New England Journal of Medicine. Substudies presented this month at IDWeek 2015 showed that this regimen is highly effective regardless of race or specific antiretroviral regimen.
More Than 2 Million People Worldwide Are Coinfected with HIV and Hepatitis C
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 23 March 2016 00:00
- Written by Liz Highleyman
Approximately 2.3 million people are living with both HIV and hepatitis C virus (HCV), about half of whom are people who inject drugs, according to a meta-analysis of nearly 800 studies published in the February 24 advance online edition of The Lancet. The analysis found that the overall likelihood of people with HIV being coinfected with HCV is about 6%, but good data are lacking for many countries.
Antiretroviral Treatment for HIV Appears to Protect Gay Men Against Hepatitis B
- Details
- Category: HIV/HBV Coinfection
- Published on Monday, 19 October 2015 00:00
- Written by Liz Highleyman
HIV-positive gay and bisexual men who use effective combination antiretroviral therapy (ART) were 80% less likely to become infected with hepatitis B virus (HBV) in a large observational study reported in the October 13 Annals of Internal Medicine. The authors emphasize, however, that ART is not a substitute for hepatitis B vaccination.
Web Design and Development by